Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(11):1961–1965. doi: 10.1038/bjc.1998.325

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

K Matsui 1, N Masuda 1, M Fukuoka 1, T Yana 1, T Hirashima 1, T Komiya 1, M Kobayashi 1, M Kawahara 1, S Atagi 1, M Ogawara 1, S Negoro 1, S Kudoh 1, K Furuse 1
PMCID: PMC2150367  PMID: 9667675

Abstract

A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

Full text

PDF
1961

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Alberto P., Bitran J., Comis R., Daniels J., Hansen H., Ikegami H., Smyth J. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep. 1983 Jan;67(1):37–43. [PubMed] [Google Scholar]
  2. Bishop J. F., Raghavan D., Stuart-Harris R., Morstyn G., Aroney R., Kefford R., Yuen K., Lee J., Gianoutsos P., Olver I. N. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol. 1987 Oct;5(10):1574–1578. doi: 10.1200/JCO.1987.5.10.1574. [DOI] [PubMed] [Google Scholar]
  3. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  4. Carney D. N. Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Lung Cancer. 1995 Jun;12 (Suppl 3):S77–S83. doi: 10.1016/s0169-5002(10)80021-2. [DOI] [PubMed] [Google Scholar]
  5. Carney D. N., Grogan L., Smit E. F., Harford P., Berendsen H. H., Postmus P. E. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol. 1990 Feb;17(1 Suppl 2):49–53. [PubMed] [Google Scholar]
  6. Cavalli F., Sonntag R. W., Jungi F., Senn H. J., Brunner K. W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978 Mar;62(3):473–475. [PubMed] [Google Scholar]
  7. Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., Roché H., Houin G., Bugat R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995 Apr 19;87(8):573–580. doi: 10.1093/jnci/87.8.573. [DOI] [PubMed] [Google Scholar]
  8. Dajczman E., Fu L. Y., Small D., Wolkove N., Kreisman H. Treatment of small cell lung carcinoma in the elderly. Cancer. 1996 May 15;77(10):2032–2038. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2032::AID-CNCR10>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  9. Dombernowsky P., Nissen N. I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A. 1973 Sep;81(5):715–724. doi: 10.1111/j.1699-0463.1973.tb03564.x. [DOI] [PubMed] [Google Scholar]
  10. Egorin M. J., Van Echo D. A., Olman E. A., Whitacre M. Y., Forrest A., Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985 Dec;45(12 Pt 1):6502–6506. [PubMed] [Google Scholar]
  11. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  12. Evans W. K., Eisenhauer E., Hughes P., Maroun J. A., Ayoub J., Shepherd F. A., Feld R. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer. 1988 Oct;58(4):464–468. doi: 10.1038/bjc.1988.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Evans W. K., Radwi A., Tomiak E., Logan D. M., Martins H., Stewart D. J., Goss G., Maroun J. A., Dahrouge S. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol. 1995 Apr;18(2):149–155. [PubMed] [Google Scholar]
  14. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855–861. doi: 10.1093/jnci/83.12.855. [DOI] [PubMed] [Google Scholar]
  15. Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic daily administration of oral etoposide--a phase I trial. J Clin Oncol. 1989 Mar;7(3):396–401. doi: 10.1200/JCO.1989.7.3.396. [DOI] [PubMed] [Google Scholar]
  16. Johnson D. H., Greco F. A., Strupp J., Hande K. R., Hainsworth J. D. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990 Oct;8(10):1613–1617. doi: 10.1200/JCO.1990.8.10.1613. [DOI] [PubMed] [Google Scholar]
  17. Luikart S. D., Goutsou M., Mitchell E. D., Van Echo D. A., Modeas C. R., Propert K. J., O'Donnell J., Difino S., Perry M. C., Green M. R. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol. 1993 Apr;16(2):127–131. doi: 10.1097/00000421-199304000-00009. [DOI] [PubMed] [Google Scholar]
  18. Miller A. A., Herndon J. E., 2nd, Hollis D. R., Ellerton J., Langleben A., Richards F., 2nd, Green M. R. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug;13(8):1871–1879. doi: 10.1200/JCO.1995.13.8.1871. [DOI] [PubMed] [Google Scholar]
  19. Pfeiffer P., Sørensen P., Rose C. Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer? Eur J Cancer. 1995;31A(1):64–69. doi: 10.1016/0959-8049(94)00370-k. [DOI] [PubMed] [Google Scholar]
  20. Schabel F. M., Jr, Trader M. W., Laster W. R., Jr, Corbett T. H., Griswold D. P., Jr cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459–1473. [PubMed] [Google Scholar]
  21. Siu L. L., Shepherd F. A., Murray N., Feld R., Pater J., Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1996 Mar;14(3):821–828. doi: 10.1200/JCO.1996.14.3.821. [DOI] [PubMed] [Google Scholar]
  22. Slevin M. L., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. F. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 1989 Sep;7(9):1333–1340. doi: 10.1200/JCO.1989.7.9.1333. [DOI] [PubMed] [Google Scholar]
  23. Smit E. F., Carney D. N., Harford P., Sleijfer D. T., Postmus P. E. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax. 1989 Aug;44(8):631–633. doi: 10.1136/thx.44.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Smith I. E., Evans B. D., Gore M. E., Vincent M. D., Repetto L., Yarnold J. R., Ford H. T. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol. 1987 Feb;5(2):185–189. doi: 10.1200/JCO.1987.5.2.185. [DOI] [PubMed] [Google Scholar]
  25. Smith I. E., Harland S. J., Robinson B. A., Evans B. D., Goodhart L. C., Calvert A. H., Yarnold J., Glees J. P., Baker J., Ford H. T. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep. 1985 Jan;69(1):43–46. [PubMed] [Google Scholar]
  26. Souhami R. L., Spiro S. G., Rudd R. M., Ruiz de Elvira M. C., James L. E., Gower N. H., Lamont A., Harper P. G. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997 Apr 16;89(8):577–580. doi: 10.1093/jnci/89.8.577. [DOI] [PubMed] [Google Scholar]
  27. Wolf M., Tessen H. W., Goerg C., Achterrath W., Drings P., Havemann K. Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC). Ann Oncol. 1991 May;2(5):361–364. doi: 10.1093/oxfordjournals.annonc.a057957. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES